A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521973-16-00

Acronym

BCX17725-101

Enrollment

Registered

2026-01-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Netherton Syndrome

Brief summary

Effectiveness : Primary Effectiveness Endpoint: • Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12, Safety : Incidence of TEAEs through End-of-Study (EOS), PK : Concentration of BCX17725 in serum through EOS

Detailed description

Effectiveness : Key Secondary Effectiveness Endpoints: • Change from baseline in Investigator Global Assessment (IGA) score at Week 12 Change from baseline in the Worst Itch Numerical Rating Scale (NRS) score at Week 12

Interventions

DRUGBCX17725

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Effectiveness : Primary Effectiveness Endpoint: • Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12, Safety : Incidence of TEAEs through End-of-Study (EOS), PK : Concentration of BCX17725 in serum through EOS	—

Secondary

Measure	Time frame
Effectiveness : Key Secondary Effectiveness Endpoints: • Change from baseline in Investigator Global Assessment (IGA) score at Week 12 Change from baseline in the Worst Itch Numerical Rating Scale (NRS) score at Week 12	—

Countries

France, Germany, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026